TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02438774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post-harvest intervention package
Description: The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine agriculture extension services
Description: This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine agriculture extension services
Description: This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
Study: NCT05543421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: rTMS (30sessions) or iTBS (40sessions)
Study: NCT04273503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring/educational session
Description: 12 mentoring/educational sessions focused on physical activity and healthy nutrition by Mayo Clinic experts.
Study: NCT00003288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Study: NCT01144221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramyocardial Cell therapy
Description: Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
Study: NCT01098357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone PDGF-BB Low dose
Description: BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone PDGF-BB High dose
Description: BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regranex
Description: Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone PDGF-BB Very Low Dose
Description: BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
Study: NCT03058016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized recommendations for diet
Description: Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
Study: NCT04579211

Intervention type: DIAGNOSTIC_TEST
Intervention: urine lipoarabinomannan (LAM)
Description: Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
Study: NCT03565588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education session with fixed incentive
Description: All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education session with lottery incentive
Description: All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures.
Study: NCT04505280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: Greater occipital nerve and cervical region injections once a week for 4 weeks
Study: NCT04425278

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation with real current
Description: transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation with sham current
Description: transcranial direct current stimulation with sham current is a placebo
Study: NCT01611077

Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan cilexetil
Description: Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
Study: NCT01843504

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
Study: NCT01133327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire.
Study: NCT01843504

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
Study: NCT02373163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
Study: NCT02028221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
Study: NCT00874276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Marker on Chromosome 14q24.3
Description: Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Marker on Chromosome 14q24.3
Description: Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
Study: NCT04883996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% EXP039
Description: 1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
Study: NCT02373163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
Study: NCT01611077

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan medoxomil
Description: Switch to olmesartan 40 mg tablets once daily for 42 days,

Intervention type: DRUG
Group type: OTHER
Intervention: Olmesartan/amlodipine
Description: then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
Study: NCT04883996

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Saline
Study: NCT05913115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA144
Description: FPA144 will be administered intravenously Q2W.
Study: NCT01867658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progel® Pleural Air Leak Sealant
Description: Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
Study: NCT03641222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Traditional Chinese Medicine (TCM) Acupuncture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Traditional Chinese Medicine (TCM) Acupuncture
Study: NCT02374112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation
Study: NCT03007563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilirubin concentration estimation from smartphone pictures
Description: pictures taken of the skin covering the breast bone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilirubin concentration measured in standard blood samples

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilirubin concentration measured by transcutaneous device
Study: NCT00997191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
Study: NCT01161524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg titrated up to 8-12 mg maximum; taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 2 mg titrated up to 8-12 mg maximum; taken once daily.
Study: NCT02716896

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation and chemoradiation
Description: Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical cystectomy
Description: Radical cystectomy will be performed on those who are randomized to this group.
Study: NCT01727700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Once-daily, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Once-daily, tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04444427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLR2007
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLR2007
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLR2007
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLR2007
Description: Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
Study: NCT05363943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double plating
Description: open reduction and internal fixation by using lateral and medial plates.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal femoral replacement
Description: excision of the distal part of femur and replacement with distal femoral prosthesis
Study: NCT04178083

Intervention type: DIAGNOSTIC_TEST
Intervention: medical examination
Description: medical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: medical examination
Description: medical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: medical examination
Description: medical examination
Study: NCT02640235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELSTAT
Study: NCT01161524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo taken once daily.
Study: NCT03078101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG [Jardiance]
Description: administered orally once daily
Study: NCT02640235

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel Original
Study: NCT01066442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649 (Pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study: NCT00997191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone
Description: Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
Study: NCT03078101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG [Jardiance]
Description: administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administered orally once daily
Study: NCT00004184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 4B5 anti-idiotype vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 4B5 anti-idiotype vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT00997191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Description: Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
Study: NCT01327365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans-radial PCI (TRI)
Description: TRI performed using the sheathless guiding approach
Study: NCT00004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alum adjuvant
Study: NCT01579201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
Study: NCT00243893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Study: NCT01327365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans-radial PCI (TRI)
Description: TRI performed using a conventional guiding approach
Study: NCT00243893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Study: NCT02551107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of nasal Nitric Oxide level
Description: ECO MEDICS CLD 88 sp Nitric Oxide Analyzer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of nasal Nitric Oxide level
Description: ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
Study: NCT03587103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol initiate with A
Description: The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol initiate with C
Description: The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol initiate with D
Description: The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
Study: NCT02912520

Intervention type: DRUG
Intervention: Anti-Bacterial Agents
Description: administration of any antibiotic substance(s) over the course of 2 weeks
Study: NCT03095976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.
Description: Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
Study: NCT03180138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders alone
Description: Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders alone
Description: Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance-linked incentives
Description: Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.